Children's Health Defense A “substantial proportion” of infants immunized against the RSV virus with the monoclonal antibody shot nirsevimab — marketed by Sanofi and AstraZeneca as Beyfortus — developed a nirsevimab-resistant strain of the illness, according to a French study.
Over 12.5% of infants with breakthrough cases of RSV following immunization had variants of the illness with “intermediate to high-level resistance” to nirsevimab, including new strains of the virus not seen previously.
“The emergence of RSV-resistance described by this paper is simply incredible,” Children’s Health Defense Senior Scientist Karl Jablonowski said. He added:
“Most studies that shed light on the emergence of pathogens resistant to prophylaxis are population-wide and after many years of their use. Examples include the pertussis vaccine, the pneumococcal vaccine and the meningitis vaccine.
“This paper appears to show, with a high degree of certainty, the genesis of resistance.”
The study, designed to monitor escape variants of the virus and published on The Lancet’s preprint server, was conducted by a team of researchers from hospitals and research institutions across France…
READ FULL ARTICLE HERE… (childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
Be First to Comment